This clinical trial is focused on studying Celiac Disease, a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, causing damage to the small intestine. The study aims to evaluate the effectiveness and safety of a new treatment called ZED1227, which is taken in the form of a hard capsule. Participants in the trial will either receive the ZED1227 capsules or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to see if ZED1227 can help improve symptoms of Celiac Disease in individuals who continue to experience symptoms despite following a gluten-free diet. The trial will involve participants taking the capsules for a period of 15 weeks. During this time, participants will continue their usual gluten-free diet and will be asked to report their symptoms using a diary specifically designed for Celiac Disease symptoms.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The trial will assess the improvement in symptoms such as diarrhea, abdominal pain, bloating, and nausea, as well as any changes in the condition of the small intestine. The study is designed to provide valuable information on whether ZED1227 can be a beneficial treatment for those with Celiac Disease who are not fully relieved by a gluten-free diet alone.